Natco Pharma's Semaglutide launch in India
Natco Pharma has launched its semaglutide injection in India, priced at Rs 1,290, following the expiration of Novo Nordisk’s patent. This move aims to provide a more affordable option for patients requiring this medication.
The launch includes semaglutide in multidose vials, with Natco seeking to improve accessibility across India. Other pharmaceutical companies are also preparing to introduce their generic versions of the drug.
This development is expected to lead to significant cost savings for Indian consumers who require semaglutide, a drug used in the treatment of diabetes and weight management.
Natco’s strategic launch aligns with the increasing demand for affordable medicines in India, potentially reshaping the market dynamics for diabetes and obesity treatments.
About the Author
